Diabetes treatment with biguanides: the pros and the cons (author's transl). 1976

H Mehnert

UI MeSH Term Description Entries
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005943 Gluconeogenesis Biosynthesis of GLUCOSE from nonhexose or non-carbohydrate precursors, such as LACTATE; PYRUVATE; ALANINE; and GLYCEROL.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001645 Biguanides Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES. Biguanide

Related Publications

H Mehnert
June 1977, Klinische Wochenschrift,
H Mehnert
December 1978, Casopis lekaru ceskych,
H Mehnert
November 1974, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
H Mehnert
May 2011, Diabetes care,
H Mehnert
September 1974, Casopis lekaru ceskych,
Copied contents to your clipboard!